Residual disease in AML, a target that can move in more than one direction-Reference-Cited by-同舟云学术

Residual disease in AML, a target that can move in more than one direction

Published:2013-11-15 Issue:1 Volume:86 Page:15-17
ISSN:1552-4949
Container-title:Cytometry Part B: Clinical Cytometry
language:en
Short-container-title:Cytometry

Author:

Loken Michael R.¹

Affiliation:

1. Hematologics; Seattle WA

Publisher

Wiley

Subject

Cell Biology,Histology,Pathology and Forensic Medicine

Reference4 articles.

1. Tumor heterogeneity makes AML a “moving target” for detection of residual disease;Zeijlemaker;Cytometry B Clin Cytom

2. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry;Terstappen;Anal Cell Path,1990

3. Flow cytometric characterization of Acute Myeloid Leukemia. Part II. Phenotypic heterogeneity at diagnosis;Terstappen;Leukemia,1991

4. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group;Loken;Blood,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives;Cancers;2024-04-15

2. Measurable Residual Disease Assessment in Pediatric AML;Pediatric Oncology;2024

3. The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease;Cytometry Part B: Clinical Cytometry;2023-04-04

4. Morphologic remission status is limited compared to ΔN flow cytometry: a Children’s Oncology Group AAML0531 report;Blood Advances;2020-10-20

5. Detection of Minimal Residual Disease;Practical Lymph Node and Bone Marrow Pathology;2020